Drug intelligence / Profile preview

Aloglutamol

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Aloglutamol is an antacid salt composed of aluminium, gluconic acid, and tris (tromethamine). It is used for the treatment of hyperacidity, esophagitis, gastritis, peptic ulcer disease, hiatal hernia, heartburn, indigestion, acid reflux, ulcers and gas. Upon administration in the stomach, its components react with hydrochloric acid to form less soluble salts and free gluconic acid. This reaction buffers gastric acidity without causing a rapid rise in pH or rebound hyperacidity. Aloglutamol is marketed under several trade names including Altris, Pyreses, Tasto and Sabro.

Brand names: AltrisPyresesTastoSabro
Other names: aloglutamoltrometamolgluconate aluminium

Beyond the preview

Go deeper on Aloglutamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aloglutamol.

Explore the full profile